Christophe Weber, Takeda CEO (Kosuke Okahara/Bloomberg via Getty Images)
July 31, 2024 01:21 PM EDT
R&D
Pharma

Take­da de­fends Alzheimer's pact, TYK2 po­ten­tial as re­struc­tur­ing is in 'full swing'

Kyle LaHucik

Senior Reporter

In its quar­ter­ly up­date on Wednes­day, Take­da ex­ec­u­tives said the Japan-based phar­ma gi­ant’s $900 mil­lion re­struc­tur­ing is in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Blue­bird bio to sell to in­vest­ment funds af­ter strug­gling to make mon­ey from gene ther­a­pies

CBER's deputy di­rec­tor de­parts as staff shake­up con­tin­ues

Will CRISPR mat­ter?

FDA ap­proves first drug to treat ul­tra-rare lipid stor­age dis­ease

FDA says Ozem­pic, We­govy short­age is over

sponsored

Trust­ed pro­tec­tion: Why the cur­rent meningo­coc­cal vac­ci­na­tion sched­ule shouldn’t change with­out strong ev­i­dence

A service from the Financial Times